Blue Matter Blog

Our Foundation: A “People First” Culture
July 30, 2020

If you’ve followed our blog for any length of time, you’ve probably noticed that we like to create high-value content on some of the leading topics in the biopharma industry.  Today, I want to shift gears and write a bit about Blue Matter as a company and its culture. We’re growing rapidly, always engaging with …

Blue Matter “Breakfast Club” Meeting #5: Practical Implications of the COVID-19 Crisis for Biopharma
July 28, 2020

The Blue Matter Breakfast Club is an ongoing series of discussion forums (now virtual due to COVID-19), hosted by our team in Europe.  These forums are by invitation, bringing together leading executives from biopharma companies and other organizations to discuss critical business issues. The fifth Breakfast Club meeting took place on 8th July 2020.  The …

T Cell-Based Therapies in Oncology: Landscape Evolution After a Turbulent 1H2020
July 7, 2020

Six months ago, we published an in-depth review of the cell-based immunotherapy landscape, including forward-facing declarations of 2020 data releases, filings, etc. that would address key outstanding questions, namely: Six months later, despite the unprecedented and unanticipated impact of COVID-19 on corporate operations, clinical trial functions, and regulatory body decision-making, there have been multiple key …